EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis
Abstract
- Publication:
-
PLoS ONE
- Pub Date:
- March 2021
- DOI:
- 10.1371/journal.pone.0247860
- Bibcode:
- 2021PLoSO..1647860Y